Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells.
FoxP3+ T cells
breast cancer
lactate
plasmacytoid dendritic cells
type I IFN
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
05
2019
accepted:
24
07
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Plasmacytoid dendritic cells are the most efficient producers of type I interferons, viz. IFNα, in the body and thus have the ability to influence anti-tumor immune responses. But repression of effective intra-tumoral pDC activation is a key immuno-evasion strategy exhibited in tumors-tumor-recruited pDCs are rendered "tolerogenic," characterized by deficiency in IFNα induction and ability to expand regulatory T cells
Identifiants
pubmed: 31440253
doi: 10.3389/fimmu.2019.01878
pmc: PMC6692712
doi:
Substances chimiques
Lactic Acid
33X04XA5AT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1878Références
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Annu Rev Immunol. 2005;23:275-306
pubmed: 15771572
Nat Immunol. 2005 Jul;6(7):722-9
pubmed: 15951814
Annu Rev Immunol. 2007;25:267-96
pubmed: 17134371
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
J Exp Med. 2007 Jan 22;204(1):105-15
pubmed: 17200410
J Immunol. 2007 Jun 15;178(12):7540-9
pubmed: 17548588
Nature. 2007 Oct 4;449(7162):564-9
pubmed: 17873860
Cell. 2007 Dec 14;131(6):1047-58
pubmed: 18083096
J Lipid Res. 2008 Apr;49(4):797-803
pubmed: 18174606
Nat Rev Immunol. 2008 Aug;8(8):594-606
pubmed: 18641647
J Immunol. 2008 Oct 15;181(8):5396-404
pubmed: 18832696
J Clin Oncol. 2009 Jan 10;27(2):186-92
pubmed: 19064967
J Exp Med. 2009 Aug 31;206(9):1983-94
pubmed: 19703986
J Immunol. 2009 Nov 15;183(10):6489-99
pubmed: 19841182
Biochem J. 2010 Jan 15;425(3):523-30
pubmed: 19929853
J Immunol. 2010 Feb 1;184(3):1200-9
pubmed: 20026743
Immunology. 2009 Nov;128(3):439-50
pubmed: 20067543
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Sci Transl Med. 2011 Mar 9;3(73):73ra19
pubmed: 21389263
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Cancer Res. 2011 Nov 15;71(22):6921-5
pubmed: 22084445
Cold Spring Harb Symp Quant Biol. 2011;76:299-311
pubmed: 22156302
Annu Rev Immunol. 2012;30:531-64
pubmed: 22224781
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Cancer Res. 2012 Oct 15;72(20):5240-9
pubmed: 22850422
Nat Med. 2013 Jan;19(1):65-73
pubmed: 23242473
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982
Nat Rev Immunol. 2013 Aug;13(8):566-77
pubmed: 23827956
Oncoimmunology. 2013 Nov 1;2(11):e26383
pubmed: 24404426
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
J Exp Med. 2014 Sep 22;211(10):1969-76
pubmed: 25180061
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
J Cereb Blood Flow Metab. 2015 Feb;35(2):176-85
pubmed: 25425080
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
J Immunol. 2016 Mar 1;196(5):2004-9
pubmed: 26826244
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Diabetes. 2016 Nov;65(11):3440-3452
pubmed: 27561727
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Trends Immunol. 2018 Jan;39(1):28-43
pubmed: 28826817
Cancer Res. 2018 Apr 1;78(7):1685-1699
pubmed: 29363545
J Immunol. 2018 Mar 1;200(5):1781-1789
pubmed: 29386257